Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan

Annals of Nuclear Medicine

Volumn 16, Issue 4, 2002, Pages 263-271

  Kosuda, Shigeru ^a   Ichihara, Kiyoshi ^b   Watanabe, Masazumi ^c   Kobayashi, Hideo ^a   Kusano, Shoichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Cost benefit analysis; Emission computed tomography; Fluorine 18 deoxyglucose; Life expectancy; Non small cell lung carcinoma

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ALGORITHM; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; HUMAN; JAPAN; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS; MORTALITY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SURVIVAL; WHOLE BODY COUNTING; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; LUNG CANCER; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; THORACOTOMY; WHOLE BODY SCINTISCANNING;

ALGORITHMS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION TREES; FLUORODEOXYGLUCOSE F18; HUMANS; JAPAN; LIFE EXPECTANCY; LUNG NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING; FLUDEOXYGLUCOSE F 18; HUMAN;

EID: 0035991872     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03000105     Document Type: Article

References (50)

1. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma
2. Cost-effectiveness of FDG-PET for staging non-small-cell lung cancer: A decision analysis
3. FDG-PET in solitary pulmonary nodules: A german cost-effectiveness analysis
4. A theoretical decision analysis model for the cost effectiveness of newly emerging coincidence imaging (CI) technology in the presurgical staging of non-small-cell lung carcinoma (NSCLC)
5. Effectiveness of whole-body FDG PET in staging of non-small-cell lung cancer (NSCLC)
6. Cost-effectiveness analysis of FDG-PET in the differential diagnosis and staging of lung cancer in Japan
7. Decision-tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary nodule (non-small-cell lung carcinoma) in Japan
8. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
9. Staging non-small-cell lung cancer by whole-body positron emission tomographic imaging
10. 18FDG positron emission tomography in the staging of non-small cell lung cancer
11. Staging non-small cell lung cancer with whole-body PET
12. Methods of cost-effectiveness analysis: Areas of consensus and debate
13. Clinical evaluation of silent brain metastasis in lung cancer patients
14. Analyzing clinical decision analysis
15. Secondary screening for lung cancer by helical CT
16. Analysis of small peripheral pulmonary tumors treated by thoracoscopic excisional biopsy (wedge resection) on a suspicion of primary lung cancer
17. Analysis of reasons for biopsy in small pulmonary nodules diagnosed by thoracoscopic and open-lung biopsy
18. Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)
19. Differential diagnosis of lung tumor with positron emission tomography: A prospective study
20. FDG PET imaging of the chest
21. Positron emission tomography of the thorax. The current clinical status
22. Satellite PET and lung cancer: A prospective study in surgical patients
23. 18F]fluoroglucose. The members of the PET-lung tumor study group
24. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography
25. Characterization of chest masses by FDG positron emission tomography
26. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer
27. F-18-FDG PET in the evaluation of small solitary pulmonary nodules
28. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
29. Bronchogenic carcinoma metastatic to normal-sized lymph nodes: Frequency and significance
30. Bronchogenic carcinoma: Analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling
31. Preoperative staging of carcinoma of the bronchus: Can computed tomographic scanning reliably identify stage III tumors?
32. Bronchogenic carcinoma: Utility of CT in the evaluation of patients with suspected lesions
33. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small-cell lung cancer
34. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-Meta-analytic comparison of PET and CT
35. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation
36. Cost-effective staging of non-small-cell lung carcinoma by whole-body PET-FDG imaging
37. Staging of lung cancer by whole-body PET-FDG imaging
38. Suspected non-small cell lung cancer: Incidence of occult brain and skeletal metastases and effectiveness of imaging for detection-pilot study
39. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
40. Outcome of lung cancer patients with surgical therapy
41. What to do when the patient outlives the literature, or DEALE-ing with a full deck
42. Assessment of cost-effective nuclear medicine practice in Japan
43. Radiologic evaluation in chest malignancies. A review of imaging modalities
44. Small adenocarcinoma of the lung. Histologic characteristics and prognosis
45. Factors influencing pneumothorax rate at lung biopsy: Are dwell time and angle of pleural puncture contributing factors?
46. Current applications of imaging procedures in the patient with lung cancer
47. Cost-effectiveness of PET imaging in clinical oncology
48. Foundations of cost-effectiveness analysis for health and medical practices